📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Peer Medians

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly used phrases like 'breakout year', 'clear path to deliver sustainable growth', 'momentum is building', and provided specific numbers (e.g., $12.5M revenue, 248 enrolled patients, 142 on treatment, PDUFA goal date Sept 7) with no hedging or vague language.

Q3 2025

Confident Specific

Management used specific language such as 'steady progress', 'clear path', 'we remain confident', and provided concrete figures like 149 patients on therapy and specific milestones (December 7 PDUFA, RISE UP data by year end). They did not hedge but addressed the REMS extension positively, though some analysts' probes were deflected.

Q4 2025

Confident Specific

Management used specific metrics (44 prescriptions, $20M revenue, 10-12 week conversion) and positive phrases like 'strong early recognition', 'very encouraged', and 'fantastic to see' to convey confidence in the ACTIVASE launch and pipeline progress.

Q1 2026 latest

Confident Specific

Management uses phrases like 'off to a strong start', 'exceptional execution', 'very encouraged', and provides specific numbers: 138% revenue growth, 242 prescriptions, $20.7M revenue. The tone is forward-looking but acknowledges early launch dynamics.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears strengthened by the strong early launch metrics (242 scripts in Q1) and the clear path to sNDA filing for mitapivat in sickle cell disease. However, management's caution against extrapolating the run rate and the lack of specific revenue guidance create uncertainty. The upcoming tebapivat data readouts in MDS and sickle cell disease will be critical to assess the next-generation pipeline potential. Next quarter should focus on prescription-to-revenue conversion, payer access progress, and any updates on the confirmatory trial design for mitapivat in sickle cell disease.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

📐

3-Statement Financial Model

Bear / Base / Bull projections · DCF fair value · Reverse-DCF

Open Model →

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Agios reports Q1 2026 net revenue of $20.7M, 138% growth, with strong AQVESME launch of 242 prescriptions.

Revenue & Profitability

First quarter 2026 worldwide net revenues were $20.7 million, representing 138% year-over-year growth. U.S. net revenues were $18.8 million, driven by the AQVESME launch, and ex-U.S. revenues were $1.9 million. R&D expense was $81 million, up roughly $8 million year-over-year due to workforce and process development efforts. SG&A expense was $48 million, up about $7 million year-over-year due to launch activities and stock compensation. Net income or operating income were not disclosed. The company ended the quarter with over $1 billion in cash and marketable securities.

Outlook

Management views the industry as having significant unmet need in rare hematology, particularly in thalassemia and sickle cell disease. They expect strong demand for AQVESME but caution that early prescription volumes do not translate into a steady run rate due to eventual movement into less motivated patient segments. The company anticipates average initiation timelines of approximately 10-12 weeks in coming quarters. For sickle cell disease, they see room for multiple treatment options and are confident in the mitapivat data set.

Growth Drivers

Key growth drivers include the U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written in Q1 2026 by REMS-certified physicians. The upcoming sNDA filing for mitapivat in sickle cell disease under the Accelerated Approval pathway is a major catalyst. Additionally, top-line phase II data for tebapivat in lower-risk MDS (first half 2026) and sickle cell disease (second half 2026) are expected to drive growth. Expansion into non-transfusion-dependent thalassemia patients and deepening payer access are near-term priorities.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Not discussed in this earnings call. Management guided that 2026 operating expenses are expected to be approximately flat compared to 2025, but no specific margin targets or profit figures were provided.

Key Risks

Management highlighted potential risks including quarterly revenue variability due to ordering patterns, inventory dynamics, and gross-to-net adjustments. Early launch demand may not translate into a steady run rate; as adoption moves to non-transfusion-dependent patients with less frequent clinical engagement, time from prescription to initiation may lengthen to the expected 10-12 weeks. Payer policy formation takes about 6 months, which could affect access. The REMS was not seen as a hurdle but could present challenges if adoption broadens rapidly.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q1 2026 Q1 2026 2026-04-29

Q1 2026 saw 138% revenue growth to $20.7M, driven by a strong AQVESME launch in thalassemia and robust U.S. demand. Mitapivat sNDA for sickle cell disease is on track for Q2, and the pipeline remains catalyst-rich with key data readouts expected this year.

Q4 2025 Q4 2025 2026-02-12

Q4 and full-year 2025 saw robust revenue growth, highlighted by the US launch of ACTIVASE for thalassemia and strong PYRUKYND performance. The company ended 2025 with $1.2B in cash, supporting a catalyst-rich 2026 focused on pipeline expansion and disciplined investment.

Q3 2025 Q3 2025 2025-10-30

Q3 2025 net revenue grew 44% year-over-year to $12.9 million, driven by PYRUKYND's commercial momentum and global regulatory progress. Strong cash reserves support upcoming U.S. launches and pipeline advancement, with key data readouts and regulatory milestones expected by year end.

Q2 2025 Q2 2025 2025-07-31

Q2 2025 net revenue grew 45% year-over-year to $12.5M, driven by PYRUKYND, with U.S. Thalassemia launch pending FDA approval and ex-U.S. expansion progressing via partnerships. Cash reserves remain strong at $1.3B, supporting continued pipeline and commercial investment.

Q1 2025 Q1 2025 2025-05-01

Q1 2025 saw 6% year-over-year revenue growth for Pyrukynd, with strong progress toward a potential thalassemia launch in September and a pivotal sickle cell disease readout by year-end. The company maintains a robust $1.4B cash position and disciplined capital allocation.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.